Abstract Details

Title Association of Serum Ferritin with Parkinsonian Disorders

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 162

Objective

Background BACKGROUND: Iron dysregulation promotes oxidative stress, a proposed pathological mechanism in neurodegenerative disease. Increased concentrations of brain iron have been demonstrated in Parkinsonian disorders. Serum ferritin remains a clinically useful tool to determine body iron load. However, the association of serum ferritin with Parkinson's disease or other Parkinsonian disorders is still unclear.

Design/Methods DESIGN/METHODS: In this retrospective study, medical records and serum ferritin levels were reviewed in patients with the diagnosis of various movement disorders including idiopathic Parkinson's disease (PD), Parkinson plus syndromes, and essential tremors seen at Stony Brook University Hospital during the period of 2006 to 2012.

Results RESULTS: Total 85 PD patients, 9 patients with Parkinson plus syndromes and 61 tremor patients had serum ferritin level checked. Of the 85 PD patients, ferritin levels were found elevated in 15 patients (17.6%). In the Parkinson plus syndromes group, 5/9 (55%) had elevated ferritin. In the tremor group, 9 patients (14.8%) had elevated ferritin. There is a significant increased ferritin level in the Parkinson plus syndromes group compared to the PD and tremor groups (P=0.015 and 0.01 respectively). There were 20 patients in PD group with dementia. Among them, seven patients (35 %) had elevated ferritin. In 65 PD patients without dementia, only 8 (12.3%) had elevated ferritin (P=0.034). Mean age between PD patients with elevated ferritin or without elevated ferritin had no difference (81.9± 6.3 vs. 79.1±10.3; P=0.32).

Conclusions CONCLUSIONS: Our study shows that increased serum ferritin is more prevalent in patient with Parkinson plus syndromes or PD with dementia. This suggests that increased body iron load measured by elevated serum ferritin may indicate a more widely involved neurodegeneration process in such patients.

Authors/Disclosures
Laura J. Wu, MD, PhD (UTMB Neurology) PRESENTER	Dr. Wu has nothing to disclose.
Oded E. Gerber, MD (SUNY Stony Brook)	No disclosure on file
Opeolu Adeoye	No disclosure on file

��ɫ��

��ɫ��